What type of study is this?

September 10, 2025Nature CommunicationsOpen Access

A broad-spectrum antibiotic targets multiple-drug-resistant bacteria with dual binding targets and no detectable resistance

View Full Paper

Ask AI

Bookmark

Authors

WHWenyan HeXi'an University of Science and Technology XHXueting HuanChina Pharmaceutical University YLY. LiHenan Polytechnic University

Discussion

Member takes

Implication

Integration of synthetic-bioinformatic and peptide optimization reveals paenimicin, showing no detectable resistance against multidrug-resistant bacteria.

Key Points

Paenimicin exhibits potent efficacy against multidrug-resistant pathogens, demonstrating a novel dual-binding mechanism.
In vitro and in vivo tests indicate that paenimicin has favorable pharmacokinetics and low nephrotoxicity.
No detectable resistance was observed with paenimicin, highlighting its potential importance in treating severe MDR infections.
The approach leverages synthetic-bioinformatic strategies to uncover antibiotic candidates within Paenibacillaceae bacteria.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/68c1a40f54b1d3bfb60ded0e https://doi.org/10.1038/s41467-025-62407-4

View Full Paper

Ask AI

Bookmark

Implication

Integration of synthetic-bioinformatic and peptide optimization reveals paenimicin, showing no detectable resistance against multidrug-resistant bacteria.

A broad-spectrum antibiotic targets multiple-drug-resistant bacteria with dual binding targets and no detectable resistance

Discussion

Member takes

Implication

Key Points

Cite This Study

A broad-spectrum antibiotic targets multiple-drug-resistant bacteria with dual binding targets and no detectable resistance

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider